42d0c1c2bd
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
- Source: inbox/queue/2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos.md - Domain: health - Claims: 2, Entities: 2 - Enrichments: 0 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
56 lines
No EOL
2.8 KiB
Markdown
56 lines
No EOL
2.8 KiB
Markdown
# Lykos Therapeutics
|
|
|
|
**Type:** Pharmaceutical company (formerly MAPS Public Benefit Corporation)
|
|
**Focus:** MDMA-assisted therapy for PTSD
|
|
**Status:** Post-CRL restructuring (75% staff reduction as of August 2024)
|
|
|
|
## Overview
|
|
|
|
Lykos Therapeutics (formerly the public benefit corporation arm of MAPS - Multidisciplinary Association for Psychedelic Studies) developed MDMA-assisted therapy for post-traumatic stress disorder. The company conducted pivotal Phase 3 trials (MAPP1 and MAPP2) that showed statistically significant reductions in PTSD symptoms measured by CAPS-5 scores.
|
|
|
|
## Regulatory History
|
|
|
|
### FDA Complete Response Letter (August 9, 2024)
|
|
|
|
The FDA rejected Lykos's New Drug Application for MDMA-assisted therapy, citing:
|
|
|
|
1. **Functional unblinding:** MDMA's pronounced psychoactive effects (empathogenic, euphoric) meant participants could reliably identify whether they received active drug or placebo, biasing self-reported outcomes. The FDA Psychopharmacologic Drugs Advisory Committee voted 10-1 that functional unblinding compromised trial validity.
|
|
|
|
2. **Data reliability concerns:** Systematic documentation issues for abuse-related adverse events and site oversight problems at clinical trial sites.
|
|
|
|
3. **Cardiovascular risk:** Acute cardiovascular effects (heart rate and blood pressure elevation) raised safety concerns for broader population use.
|
|
|
|
4. **Insufficient duration data:** Inadequate data to guide clinicians on duration of MDMA's therapeutic effects.
|
|
|
|
The FDA required an additional Phase 3 study. No resubmission timeline has been announced as of May 2026.
|
|
|
|
### FDA Advisory Committee Review (June 4, 2024)
|
|
|
|
- **Benefit-risk vote:** 8-1 adverse
|
|
- **Functional unblinding vote:** 10-1 adverse (essentially unanimous that blinding failure invalidated trial methodology)
|
|
|
|
## Organizational Impact
|
|
|
|
- Laid off approximately 75% of staff following the Complete Response Letter
|
|
- Separated operations from MAPS PBC (nonprofit parent organization)
|
|
- Meeting with FDA to request reconsideration and discuss resubmission pathway
|
|
|
|
## Clinical Trial Program
|
|
|
|
**Phase 3 Trials:**
|
|
- MAPP1 and MAPP2 showed statistically significant PTSD symptom reductions
|
|
- Used inert placebo comparator (later identified as methodological flaw)
|
|
- Efficacy demonstrated but methodology deemed invalid by FDA
|
|
|
|
## Timeline
|
|
|
|
- **2024-06-04** — FDA Psychopharmacologic Drugs Advisory Committee votes 10-1 against approval based on functional unblinding concerns
|
|
- **2024-08-09** — FDA issues Complete Response Letter rejecting NDA, requiring additional Phase 3 study
|
|
- **2024-08** — Lykos lays off ~75% of staff following CRL
|
|
- **2025-09-04** — Complete Response Letter made public
|
|
|
|
## Sources
|
|
|
|
- FDA Complete Response Letter, August 9, 2024
|
|
- Psychiatric Times coverage, September 2025
|
|
- STAT News reporting, October 2025 |